Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Background Co-inhibition of poly (ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …

Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …

The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

Background Enzalutamide, an androgen-receptor inhibitor, has been associated with
improved overall survival in men with castration-resistant prostate cancer. It is not known …

Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …

The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …